Gene: PAM
Official Full Name: peptidylglycine alpha-amidating monooxygenaseprovided by HGNC
Gene Summary: This gene encodes a multifunctional protein. The encoded preproprotein is proteolytically processed to generate the mature enzyme. This enzyme includes two domains with distinct catalytic activities, a peptidylglycine alpha-hydroxylating monooxygenase (PHM) domain and a peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL) domain. These catalytic domains work sequentially to catalyze the conversion of neuroendocrine peptides to active alpha-amidated products. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO01545 | PAM Knockout cell line (HeLa) | Human | PAM | 1:3~1:6 | Negative | Online Inquiry |
KO01546 | PAM Knockout cell line (HCT 116) | Human | PAM | 1:2~1:4 | Negative | Online Inquiry |
KO01547 | PAM Knockout cell line (HEK293) | Human | PAM | 1:3~1:6 | Negative | Online Inquiry |
KO01548 | PAM Knockout cell line (A549) | Human | PAM | 1:3~1:4 | Negative | Online Inquiry |
PAM Gene Knockout Cell Lines are genetically modified cell lines specifically engineered to lack the expression of the PAM gene, a component implicated in various biological processes, including gene editing and signal transduction pathways. These knockout cell lines serve as invaluable tools for researchers investigating the role of the PAM gene in cellular functions, disease mechanisms, and therapeutic strategies.
The primary function of PAM Gene Knockout Cell Lines lies in their ability to provide insights into the biological pathways mediated by PAM. By utilizing CRISPR/Cas9 technology or other gene-editing approaches, these cell lines facilitate the examination of gene function, interaction networks, and the cellular responses upon the absence of PAM. This capability enables scientists to model various physiological and pathological conditions, deepening our understanding of gene-driven diseases and potential treatments.
In research and clinical settings, these knockout cell lines play a pivotal role in drug development, functional genomics, and biomarker discovery. Their utility extends to screening potential pharmacological agents and studying the effects of PAM depletion on cellular behaviors, enriching the arsenal of precision medicine.
The advantages of PAM Gene Knockout Cell Lines over traditional models include the specificity of gene editing, the reproducibility of results, and the ability to create stable cell lines that maintain the knockout feature over extended periods. This specificity minimizes off-target effects often associated with other gene manipulation techniques, thereby enhancing experimental reliability.
For researchers, clinicians, and biotechnology professionals, these cell lines are essential for advancing knowledge in gene function and facilitating the development of novel therapeutics. The precision offered by PAM Gene Knockout Cell Lines allows for targeted investigations that are vital for driving innovation in drug discovery and molecular biology.
Our company boasts extensive expertise in the development and characterization of advanced biological products tailored for research applications. With a commitment to quality and innovation, we provide scientists with tools that empower their discoveries and support breakthroughs in life sciences.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.